This article is more than 5 years old. Information may no longer be current.

CA125 levels predicted outcome in high-risk ovarian cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Society for Gynecologic Oncologists’ 2010 Annual Meeting

Normalization of CA125 after the first cycle of chemotherapy predicted recurrence and survival in women with high-risk, early-stage epithelial ovarian cancer, according to the findings of the Gynecologic Oncology Group 157 study.

Researchers examined data of 213 women with complete CA125 information who were enrolled in a phase-3 trial after primary surgery. Patients had been treated with three or six cycles of carboplatin/paclitaxel.

John K. Chan, MD, assistant professor, director of gynecologic oncology, department of obstetrics and gynecology, the University of California, San Francisco, presented these findings at The Society for Gynecologic Oncologists’ 2010 Annual Meeting on Women’s Cancer in San Francisco.

Seventy-four percent of patients achieved normal CA125 levels after one cycle of chemotherapy; 88% achieved normal CA125 levels after two cycles. Eighty-one percent of women had recurrence-free survival with normalized CA125 after one cycle of therapy vs. 65% of women after two cycles (P=.012).

After one cycle of chemotherapy, the rate of recurrence-free survival was 87% in patients who had CA125 that changed from normal to normal; recurrence-free survival was 80% for those whose levels changed from elevated to normal; and 68% for those whose levels changed from elevated to elevated. OS was 92% for changes from normal to normal, 88% for elevated to normal and 77% for elevated to elevated (P=.009).

Normal levels of CA125 after the first cycle were associated with recurrence-free survival (HR=2.4; 95% CI, 1.48-3.92) and OS (HR=2.23; 95% CI, 1.31-3.78).

“CA125 is an important prognostic factor and may help us individualize treatment in subgroups of these patients with early-stage, high-risk disease,” Chan said during the presentation. – by Christen Cona

For more information:

• Chan J. #36. Presented at: The Society for Gynecologic Oncologists’ 2010 Annual Meeting on Women’s Cancer; March 14-17, 2010; San Francisco.

More Meeting Highlights>>

Follow HemOncToday.com on Twitter.